Edgewise Therapeutics Inc.

---

Edgewise boosts R&D spending with drug trials underway

 November 7, 2024 2:33:42 pm

---

Edgewise adds biotech industry adviser to board

 May 8, 2024 1:47:02 pm

---

European agency grants orphan status to Edgewise drug

 April 24, 2024 12:24:00 pm

---

Edgewise reports loss as it continues trials

 February 23, 2024 11:47:00 am

---

Edgewise expects to raise $240M with stock offering

 January 22, 2024 4:36:56 am

---

FDA grants orphan status to Edgewise’s muscular dystrophy drug

 December 1, 2023 2:00:33 pm

---

Edgewise’s R&D costs rise as drug candidates proceed through trials

 November 10, 2023 11:18:49 am

---

Increased R&D spending results in larger loss for Edgewise

 May 11, 2023 3:19:07 pm

---

Edgewise grows R&D expenses, losses in fourth quarter

 February 23, 2023 2:11:22 pm

---

Edgewise Therapeutics reports continued successful drug trials, $17.4M loss in third quarter   

 November 3, 2022 3:15:15 pm

Next Page »